http://www.synchroline.com/prodotti.asp?ID=317&N=C&P=Lipoacid
http://www.skinmed.co.uk/clinical/access/products/lipoacid.html

文獻：
1. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial.
http://www.ncbi.nlm.nih.gov/pubmed/17953631
Clin Exp Dermatol.2007 Nov;32(6):631-6.

RESULTS: In total, 28 patients completed the study. After 2 months of AP supplementation, the catalase activity and the production of reactive oxygen species (ROS) were 121% and 57% of the basal values (P < 0.05 and P < 0.02 vs. placebo, respectively). The AP increased the therapeutic success of NB-UVB, with 47% of the patients obtaining > 75% repigmentation vs. 18% in the placebo group (P < 0.05). An increase in catalase activity to 114% (P < 0.05 vs. placebo) and decrease in ROS level of up to 60% (P < 0.02 vs. placebo) of the basal value was observed in PBMCs. Finally, the AP intake maintained the membrane lipid ratio (saturated : unsaturated fatty acids 1.8 : 3.1; P < 0.05), counteracting phototherapy-induced saturation.

CONCLUSIONS: Oral supplementation with AP containing alpha-lipoic acid before and during NB-UVB significantly improves the clinical effectiveness of NB-UVB, reducing vitiligo-associated oxidative stress.

2. Treatment of vitiligo with narrow-band UVB and topical gel containing catalase and superoxide dismutase.
http://www.ncbi.nlm.nih.gov/pubmed/17433173
Acta Dermatovenerol Croat.2007;15(1):10-4
The study showed that the combination therapy of narrow-band UVB and gel containing catalase and dismutase is a therapeutic option that could be considered in the management of vitiligo. Further evaluation of this combination in multicenter, double-blind, placebo-controlled studies should be undertaken.

本站文章版權所有，歡迎非商業性『部份』轉載（請勿全文轉載），轉載請註明作者姓名標示與出處，禁止更動內文，並提供有效的該篇文章超連結。